Steve Kirsch and Kyle Beattie have been going through the documents from the Pfizer Covid vaccine trial that the company has been compelled to release (150 so far with many more to come). While they warn that their findings are preliminary and need double-checking, here are some of the key points from their analysis so far.
1. Despite recent claims that the vaccines were only ever intended to reduce serious illness, it’s clear in the documents (see excerpts below) that Pfizer’s submission to the FDA was for a vaccine that would provide: “Active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 16 years of age and older.” This purpose of the drug is stated repeatedly. That’s what it’s supposed to do, what it was authorised for. This means it has failed on its own terms, and it is unclear why this should not invalidate the authorisation in the eyes of the approving body.
2. A high number of adverse events were observed, and it was clear that many were reactions to the vaccine as they were much higher in the vaccine arm and increased with each dose.